Vojmir Urlep, President of the Board of Management of Lek, a Sandoz company, receives award for outstanding business achievements from the Chamber of Commerce and Industry of Slovenia
Today, for the 45th time in a row, the Chamber of Commerce and Industry of Slovenia (CCIS) presented awards for outstanding business and entrepreneurial achievements in recognition of those executives who over many years have successfully led their companies. This year there are 8 award winners, from four Slovenian regions and eight different branches of industry. The award among large companies was given to Vojmir Urlep, President of the Board of Management of Lek, a Sandoz company.
“The Chamber of Commerce and Industry of Slovenia award for outstanding business achievements is a result of professional, ambitious and devoted work of almost three-thousand employees of our company. They are proving every day that we know how, we want to and we can win in challenging competitive circumstances on the global markets. We achieve our successes as part of one of the largest global pharmaceutical companies, though showing that foreign investments can support business development in Slovenia. But only if it comes into the environment where knowledge, expertise, hard work, positive attitude and courage are valued,” said Vojmir Urlep upon receiving the award.
The CCIS awards for outstanding business and entrepreneurial achievements are the oldest and most prestigious awards of their kind in Slovenia. The award highlights the important correlation between the leading manager and the company itself that becomes written into the history of the Slovenian economy.
In evaluating the achievements, 69 different criteria are taken into account, from company’s general developmental results, business results and internationalisation to rapid and effective market expansion of the company, vision and clear long-term strategy, in-house development and innovation.
The award is given away in three categories (large, medium and small enterprises) and in each category three awards can be given at the most.
Winners of CCIS 2012 awards were (in alphabetical order):
|Andrej Gradišnik, General Manager||Metal Ravne, d.o.o.|
|Marjana Lavrič Šulman, Director||Futura DDB d.o.o.|
|Emil Marinšek, Director||MAREMICO, d.o.o.|
|Petra Melanšek, Director||VIVAPEN d.o.o.|
|Janez Novak, Director||RLS d.o.o.|
|Andrej Repše, Director||ARMAT PROJEKT d.o.o.|
|Dejan Turk, President of the Board of Management||Si.mobil, d.d.|
|Vojmir Urlep, President of the Board of Management||Lek Pharmaceuticals d.d.|
Lek, a Sandoz company, is one of key pillars of the second-largest generic pharmaceutical company globally. Its role within Sandoz is to act as: a leading global development center for products and technologies; a global manufacturing center for active pharmaceutical ingredients and medicines; a competence center for the development of vertically integrated products; a Sandoz competence center in the field of development and manufacturing of biosimilar products; and, a supply center for the markets of Central and Eastern Europe (CEE), South East Europe (SEE) and Commonwealth of Independent States (CIS), and it is responsible for sales on the Slovenian market. For further information please visit http://www.lek.si/eng/.
Sandoz, a Division of the Novartis group, is the second-largest generic pharmaceuticals company globally, offering a broad range of over 1,000 high-quality, affordable products that are no longer protected by patents. With approximately 25,000 employees in 140 countries, Sandoz holds the #1 position globally in biosimilars as well as generic injectables, ophthalmics, dermatology and antibiotics. Key product groups include antibiotics, treatments for central nervous system disorders, gastrointestinal medicines, cardiovascular treatments and hormone therapies. Sandoz develops, produces and markets these medicines along with pharmaceutical and biotechnological active substances and anti-infectives. In addition to strong organic growth in recent years, Sandoz has made a series of acquisitions including Lek (Slovenia), Sabex (Canada), Hexal (Germany), Eon Labs (US), EBEWE Pharma (Austria), Oriel Therapeutics (US) and Fougera Pharmaceuticals (US). In 2012, Sandoz posted sales of USD 8.7 billion. For more information, please visit http://www.sandoz.com.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 128,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.
This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.
For additional information contact:
Lek Pharmaceuticals d. d.
Phone: +386 1 580 22 43
Fax: +386 1 580 24 32